- Home
- » Tags
- » Bavarian Nordic
Top View
- Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/Rabavert and Encepur from Glaxosmithkline
- Johnson & Johnson Announces Major Commitment to Speed Ebola
- Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
- Bavarian Nordic Receives Additional Smallpox Vaccine Order from the Canadian Government
- VAC2VAC Vaccine Batch to Vaccine Batch Comparison by Consistency Testing VAC2VAC GOAL & PARTNERS
- Bavarian Nordic Announces First Half 2020 Results
- Bavarian Nordic – in TRANSITION Forward-Looking Statements
- Ebola Vaccines
- Annual Report 2016 (PDF)
- Bavarian Nordic A/S - Registration of Share Capital Increase of 5,150,000 New Shares Completed
- A Single Dose of the Mva-Bn Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is a Vaccine for Monkeypox
- Bavarian Nordic Receives Order to Manufacture Additional Ebola Vaccines
- Bavarian Nordic A/S Completes Registration of Share Capital Increase
- Bavarian Nordic, Inc. Study Protocol
- Updated Recommendations from the World Health Organization Further Support Use of Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic
- Emergency Response Worksheet
- Jynneos-Pi.Pdf
- Bavarian Nordic Announces Closing of Acquisition of Rabipur/Rabavert and Encepur from Glaxosmithkline and Updates Year-End Cash Preparedness
- Interim Results As of March 31, 2021
- Bavarian Nordic Announces First Half 2021 Results
- Our Commitment to Combating Ebola
- Durable Natural Killer Cell Responses After Heterologous Two-Dose Ebola
- Study Protocol
- Smallpox and Monkeypox Vaccine, Live, Non-Replicating) for Prevention of Smallpox and Monkeypox Disease in Adults
- Bavarian Nordic Announces Interim Results for the First Nine Months of 2019
- Bavarian Nordic Investor Presentation March 2021
- Annual Report 2019 Management Commentary / Financial Statements Group / Financial Statements Parent CONTENTS
- Bavarian Nordic Announces Interim Results for the First Nine Months of 2020
- Mva Platform Partnership Mva-Bn: Licensed Vaccine Platform
- Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from Glaxosmithkline
- The Ebola Research Database Hosted by in Collaboration with The
- [Product Monograph Template
- Mvabea, INN-Ebola Vaccine
- Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine
- September 24, 2019 Summary Basis for Regulatory Action
- Department of Health and Human Services National
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program